Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed about the change in role of Amit Bhakri, currently the Business Unit Director - Biopharmaceutical Business Unit. He will be transitioning from the said role with effect from close of business hours on March 31, 2024, as he takes up another responsibility within AstraZeneca group. Further, it has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ayush Kumar Agarwal as Business Unit Director- Biopharmaceutical Business Unit with effect from April 1, 2024. Currently he is the Director – Commercial excellence and will continue leading the same in the interim till a replacement for the said position is filled. In this regard, it has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 attached as Annexure – A.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: